Fresh analysis reveals that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt conventional lifestyle programs.
Findings released in a major medical journal shows that while obese individuals frequently drop substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"People buying such treatments must be cognizant of the potential of rapid rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to original weight within about 18 months.
Comparing Approaches
The study, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with other pills.
The team note that people who shed pounds through dieting usually experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Experts suggest the mode of action of the jabs accounts for the accelerated regain.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making binge eating much more probable."
An Ongoing Issue?
Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals contend that, considering the high risk of relapse, the therapy should be considered life-long.
This view is reinforced by drug manufacturers, who say that the findings "highlight the chronic character of obesity," akin to managing diseases like diabetes.
User Accounts
Individuals who have stopped the medication explain a intense return of hunger.
"I experienced a switch activating and you become ravenous," said a patient.
This challenge is compounded if individuals have not developed sustainable lifestyle or habit changes during treatment.
Growing Adoption
Figures suggest that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
Ultimately, experts caution that while the jabs are powerful tools for weight loss, they are not a permanent solution and lasting health benefits hinges on combined behavioural support.
